These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 21940313)

  • 1. Serial changes in cytokine expression in irritable bowel syndrome patients following treatment with calcium polycarbophil.
    Chiba T; Sato K; Toya Y; Endo K; Abiko Y; Kasugai S; Saito S; Oana S; Kudara N; Endo M; Suzuki K
    Hepatogastroenterology; 2011; 58(110-111):1527-30. PubMed ID: 21940313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colonic transit, bowel movements, stool form, and abdominal pain in irritable bowel syndrome by treatments with calcium polycarbophil.
    Chiba T; Kudara N; Sato M; Chishima R; Abiko Y; Inomata M; Orii S; Suzuki K
    Hepatogastroenterology; 2005; 52(65):1416-20. PubMed ID: 16201086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of polycarbophil Ca on IBS].
    Mine T
    Nihon Rinsho; 2006 Aug; 64(8):1483-6. PubMed ID: 16898617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium polycarbophil compared with placebo in irritable bowel syndrome.
    Toskes PP; Connery KL; Ritchey TW
    Aliment Pharmacol Ther; 1993 Feb; 7(1):87-92. PubMed ID: 8439642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Physicochemical and pharmacological characteristic and clinical efficacy of an anti-irritable bowel syndrome agent, polycarbophil calcium (Polyful)].
    Iwanaga Y
    Nihon Yakurigaku Zasshi; 2002 Mar; 119(3):185-90. PubMed ID: 11915521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory cytokines and oxidative stress biomarkers in irritable bowel syndrome: Association with digestive symptoms and quality of life.
    Choghakhori R; Abbasnezhad A; Hasanvand A; Amani R
    Cytokine; 2017 May; 93():34-43. PubMed ID: 28506572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium polycarbophil (Mitrolan).
    Med Lett Drugs Ther; 1981 May; 23(11):52. PubMed ID: 7015097
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of irritable bowel syndrome.
    Trinkley KE; Nahata MC
    J Clin Pharm Ther; 2011 Jun; 36(3):275-82. PubMed ID: 21545610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laxative and anti-diarrheal activity of polycarbophil in mice and rats.
    Saito T; Mizutani F; Iwanaga Y; Morikawa K; Kato H
    Jpn J Pharmacol; 2002 Jun; 89(2):133-41. PubMed ID: 12120755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pro-inflammatory and anti-inflammatory cytokine response in diarrhoea-predominant irritable bowel syndrome patients.
    Rana SV; Sharma S; Sinha SK; Parsad KK; Malik A; Singh K
    Trop Gastroenterol; 2012; 33(4):251-6. PubMed ID: 23923350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic cytokines are elevated in a subset of patients with irritable bowel syndrome but largely unrelated to symptom characteristics.
    Bennet SMP; Palsson O; Whitehead WE; Barrow DA; Törnblom H; Öhman L; Simrén M; van Tilburg MAL
    Neurogastroenterol Motil; 2018 Oct; 30(10):e13378. PubMed ID: 29797382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum cytokine profiles in relapsing polychondritis suggest monocyte/macrophage activation.
    Stabler T; Piette JC; Chevalier X; Marini-Portugal A; Kraus VB
    Arthritis Rheum; 2004 Nov; 50(11):3663-7. PubMed ID: 15529362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical evaluation of calcium-polycarbophil in the treatment of non-specific diarrhea].
    Gizzi G; Villani V; Rubinetto MP; Cianci M; La Froscia A; Barbara L
    Minerva Gastroenterol Dietol; 1993 Sep; 39(3):139-43. PubMed ID: 8286486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome.
    Leventer SM; Raudibaugh K; Frissora CL; Kassem N; Keogh JC; Phillips J; Mangel AW
    Aliment Pharmacol Ther; 2008 Jan; 27(2):197-206. PubMed ID: 17973974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium polycarbophil improves constipation in non-traumatic spinal cord disorders.
    Sakakibara R; Yamaguchi T; Uchiyama T; Liu Z; Yamamoto T; Ito T; Odaka T; Hattori T
    Clin Auton Res; 2006 Aug; 16(4):289-92. PubMed ID: 16810464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors.
    Dinan TG; Clarke G; Quigley EM; Scott LV; Shanahan F; Cryan J; Cooney J; Keeling PW
    Am J Gastroenterol; 2008 Oct; 103(10):2570-6. PubMed ID: 18785949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of serum macrophage migration inhibitor factor and monocyte chemotactic protein-1 levels in irritable bowel syndrome.
    Tülübaş F; Oran M; Mete R; Turan F; Yilmaz A; Yildiz ZD; Gürel A
    Turk J Med Sci; 2014; 44(6):967-71. PubMed ID: 25552148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered levels of cytokines in patients with irritable bowel syndrome are not correlated with fatigue.
    Vara EJ; Brokstad KA; Hausken T; Lied GA
    Int J Gen Med; 2018; 11():285-291. PubMed ID: 30013383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies.
    Johanson JF
    Neurogastroenterol Motil; 2004 Dec; 16(6):701-11. PubMed ID: 15601419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum immune biomarkers in irritable bowel syndrome.
    Seyedmirzaee S; Hayatbakhsh MM; Ahmadi B; Baniasadi N; Bagheri Rafsanjani AM; Nikpoor AR; Mohammadi M
    Clin Res Hepatol Gastroenterol; 2016 Nov; 40(5):631-637. PubMed ID: 26850360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.